Company intelligence / Profile preview

Stem Cell Institute

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

Over 55,000 procedures performed since 2006 using proprietary mesenchymal stem cell populations with published safety data, quality-controlled expansion, and international collaborations; primarily treats chronic degenerative and autoimmune conditions, with published observational/prospective results, but not marketed as a registrational trial sponsor.

Therapeutic areas: PsychiatryImmunologyGastroenterologyNeurologyPulmonologyEndocrinologyRheumatology
Modalities: Stem cell therapyCell therapyMesenchymal stem cell therapy
Industry: Biotech

Drug pipeline

3 assets

Golden Cells

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Saint John’s Cancer InstitutePacific Neuroscience InstituteUniversity of Miami School of MedicineUniversity of Puerto Rico School of Public Health

Beyond the preview

Go deeper on Stem Cell Institute.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stem Cell Institute.

Explore the full profile